BioFocus extends collaboration with Usher III InitiativeBioFocus announced today that it has expanded a collaboration with the Usher III Initiative, Inc., a non-profit organization focused on developing treatments for Usher syndrome type III, a rare genetic disorder that causes the loss of hearing and vision.
BioFocus and the Usher III Initiative began their collaboration in July 2010 with BioFocus performing an integrated drug discovery program encompassing medicinal chemistry, ADME and biological sciences, aiming at a small-molecule therapy for Usher syndrome type III. Under the terms of the extended agreement, BioFocus will further advance the project with the objective of delivering a pre-clinical candidate.
“The extension of this collaboration is testament to the quality of the scientific input that BioFocus offers its clients,” said Dr Chris Newton, Senior Vice President Galapagos Services. “The quality of the science at BioFocus enables it to sustain its position as a premier provider in drug discovery services.”
“We are pleased with the progress BioFocus has made thus far on discovering potential therapies for Usher syndrome. BioFocus’ approach fits very well with our aim of getting therapies into the clinic quickly and efficiently,” said Dr. David Saperstein, Scientific Director, Usher III Initiative, Inc.
About Usher III Initiative, Inc.
The Usher III Initiative, Inc. is a non-profit organization dedicated to developing cures for blindness associated with Usher syndrome type III. The Initiative funds research at universities and contract research organizations in the United States and Europe. More info is available at: www.usheriii.org
BioFocus delivers drug discovery solutions through a comprehensive platform run by dedicated teams with a track record in gene-to-clinical candidate discovery. BioFocus’ offering includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry and ADME/PK services, supported by unique chemogenomic and informatics tools. As a service division of Galapagos, BioFocus has over 210 employees with research facilities in three countries. More info at: www.biofocus.com
BioFocus® and SilenceSelect® are trademarks of Galapagos NV and/or its affiliates © Copyright 2011 Galapagos NV.
Office 3 Universal Marina | Crableck Lane | Sarisbury Green | Southampton | SO31 7AL | UK
Tel: +44 1799 533 500
Alto Marketing Limited:
Tel: +44 1489 557 672
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release BioFocus extends collaboration with Usher III Initiative here
News-ID: 180758 • Views: 2034
More Releases from BioFocus
Argenta and BioFocus announce two-year extension of drug discovery collaboration …
Galapagos NV (Euronext: GLPG) announced today that its service division Argenta has extended its integrated contract drug discovery agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). Total potential value of the contract extension is up to £21.5 million (€23.4 million). This is the third such extension since the agreement was announced in December 2005. The agreement covers a number of drug discovery
BioFocus and InterMed Discovery announce Marketing Collaboration
BioFocus, an integrated drug discovery service partner, and InterMed Discovery GmbH (IMD), a natural product lead-discovery company, today announced a marketing collaboration to offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries. No financial details were disclosed. Under the terms of the collaboration, IMD will make its natural product screening libraries available and provide follow-on services to BioFocus. BioFocus will then incorporate these as part of
BioFocus enters collaboration with Michael J. Fox Foundation
BioFocus announced today that it has signed a collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease. Under the agreement, BioFocus will perform fragment-based screening, assay development and hit-finding programs, to identify compounds that have the basis for a novel Parkinson’s disease diagnostic test. “We are delighted to have the opportunity to support The Michael J.
Astellas Pharma and BioFocus sign target discovery agreement
BioFocus announced today that it has signed a collaboration agreement with Astellas Pharma Inc. focused on discovering novel targets in the field of CNS disorders. Under the agreement, BioFocus will utilize its SilenceSelect® target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration. “We are delighted to support Astellas Pharma
More Releases for Usher
The Satellite Payloads Market to usher predictive maintenance
Optimal selection of satellite payloads has a governing influence on maximizing the utility of the satellite. However, manufacturers continue to struggle in development of satellite payloads under power supply constraints associated with satellite buses. In spite of attaining surplus investments, companies operating in the global satellite payload market continue to rely on experimental solutions for eliminating such shortcomings. According to Persistence Market Research, the global market for satellite payloads is
The Mobile Crushers And Screeners Market to usher predictive maintenance
Mobile crushers and screeners are adaptable to all kinds of mobile crushing operations in the thriving mining industry. Low transportation costs and flexible configuration, combined with easy maintenance are some of their highlighting features, which make the equipment more reliable. Mobile crushers and screeners can be customized on an operation basis, and also be combined with other machines in a production line. Mobile crushers and screeners specialize in introducing the
Author Alex Usher Releases Science Fiction Novel - Malcolm Of Earth
Alex Usher is pleased to announce the release of his new science fiction novel, Malcolm Of Earth. Published in March 2022, the book is already receiving rave reviews from readers and reviewers. They took him from his world to end a war on theirs…they got more than they bargained for. Malcolm Fletcher, a brilliant young engineer living in post-WW1 Great Britain, is kidnapped by extra-terrestrials to help end a centuries-old interplanetary
Lets Lend a Helping Hand and Usher in Christmas
Giving isn’t about making a donation; it’s about making a difference. And Team Fullestop is all set to make that difference. One of the leading Digital Agencies in India with footprints in the UK and Thailand, Fullestop is a 16-year-old firm that has been catering to a diverse global clientele. With a professional and seasoned team steered by a seasoned management team at the helm, the company offers a range of
Global Rice Husk Ash Market 2018 - Usher Agro, Deelert Group
Apex Market Reports, recently published a detailed market research study focused on the “Rice Husk Ash Market” across the global, regional and country level. The report provides 360° analysis of “Rice Husk Ash Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Rice
New market study on Usher Syndrome - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Usher Syndrome Pipeline Review, H2 2016, provides an overview of the Usher Syndrome (Genetic Disorders) pipeline landscape. Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration, prolonged, unprotected exposure to sunlight may accelerate vision loss.